Generate:Biomedicines

Generate:Biomedicines is a next-generation biotechnology company integrating machine learning, bioengineering, and medicine to revolutionize therapeutic protein design. Through its proprietary Generative Biology™ approach, the company enables the programming of protein-based therapeutics, fundamentally transforming the way drugs are discovered and developed. Headquartered in Somerville, Massachusetts, Generate:Biomedicines is a venture of Flagship Pioneering, founded on the principle that biological systems are programmable and can be systematically engineered to produce therapeutic proteins.

Generative Biology™ Approach

Generative Biology™ represents a data-driven and computational framework that moves beyond trial-and-error methods in drug development. This approach extracts generalizable biological principles from the sequence and structural data of millions of natural proteins. Using advanced machine learning algorithms, Generate:Biomedicines models the relationships between amino acid sequences, protein structure, and biological function to create novel protein sequences not found in nature.

These insights allow the company to design proteins with specific therapeutic properties—including antibodies, enzymes, gene therapy components, and complex protein architectures—which can be precisely tailored for diverse clinical applications.

At the core of this process lies the Generate Platform, built upon a “Generate–Build–Measure–Learn” cycle:

1. Generate: Algorithms propose protein sequences designed to address defined therapeutic questions.
2. Build: The sequences are synthesized and expressed in laboratory systems.
3. Measure: The physical and functional properties of the proteins are evaluated.
4. Learn: The resulting data feed back into the algorithms, continually improving model accuracy.

This iterative framework enables the rapid and systematic validation of newly designed proteins, significantly reducing drug discovery timelines.

Research and Development Focus

Generate:Biomedicines’ research programs focus on immunology, oncology, and infectious diseases. Its clinical-stage pipeline includes:

• GB-0895 for asthma
• GB-7624 for atopic dermatitis
• GB-6537 for ulcerative colitis
• GB-0669 for COVID-19

The company also collaborates with major pharmaceutical partners such as Novartis and Amgen on multiple co-development projects. In addition, Generate is pioneering the design of de novo protein–protein interactions and immune-evasive proteins, expanding the frontiers of therapeutic biology.

Leadership

Michael Nally serves as Chief Executive Officer and Flagship Pioneering CEO-Partner. The company was co-founded by Molly Gibson and Gevorg Grigoryan. The Board of Directors is chaired by Noubar Afeyan (Founder and CEO of Flagship Pioneering) and includes distinguished members such as Frances Arnold (Nobel Laureate in Chemistry) and Stéphane Bancel (CEO of Moderna).

Ethics and Responsible Innovation

Generate:Biomedicines is a signatory to the Responsible AI x Biodesign initiative, advocating the responsible use of artificial intelligence in biotechnology. The company collaborates with regulatory agencies and academic institutions to advance ethical and safety standards for AI-enabled biodesign.

Infrastructure

In addition to its headquarters in Somerville, Generate operates research and development facilities in Boynton Yards and Andover, Massachusetts, encompassing over 140,000 square feet of laboratory and computational infrastructure. Across these facilities, more than 42,000 protein sequences have been generated, analyzed, and tested. The company integrates wet-lab experimentation and computational modeling under one roof to create a unified environment for rapid biological design and validation.